Some of you may remember that small trials of Ecopipam, a D1 antagonist were carried out by William Ondo inTexas in 2019 and showed encouraging initial results in treating Augmentation on Dopamine Agonists.
tandfonline.com/doi/full/10...
Dr Stefan Clements at East Carolina University then applied for a patent to use Ecopipam for Augmentation caused by dopamine agonists. This was granted and Emalex biosciences has now been given a manufacturing licence.
There have been larger studies taking place so hopefully we will hear the results soon.
If Ecopipam can successfully dampen the D1 receptors that cause Augmentation, that would give hope to hundreds of thousands of RLS patients taking dopamine agonists.